HB 1099 — reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

26.293.1926.293.20 101st Legislative Session 1099 South Dakota Legislature House Bill 1099 IntroducedENROLLED by:A N ACT ENTITLED An Act to reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

RepresentativeB RehfeldtE AnIT ActENACTED toBY rescheduleTHE theLEGISLATURE pharmaceuticalOF compositionTHE ofS crystallineTATE polymorphOF psilocybinS inOUTH aD drugAKOTA product: approved by the Food and Drug Administration as a Schedule IV controlled substance.

B E IT ENACTED BY THE L EGISLATURE OF THE STATE OF SOUTH D AKOTA :

Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of such the salts, isomers, and salts of isomers is possible within the specific chemical designation:

Overstrikes26.293.20 indicate2 deleted1099 language.(17) Peyote, except when used as a sacramental in services of the Native American church, in a natural state that is unaltered, except for drying or curing and cutting or slicing;

26.293.19 2 1099 (17) Peyote, except that when used as a sacramental in services of the Native American church, in a natural state which that is unaltered, except for drying or curing and cutting or slicing, it is hereby excepted;

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.3 1099 (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);

26.293.19 3 1099 (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);

Methylenedioxy- OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.4 1099 alpha-pyrrolidinobutiophenone (MDPBP);

26.293.19 4 1099 alpha-pyrrolidinobutiophenone (MDPBP);

Any compound containing a 2-(1- naphthoyl)indole or 3- (1-naphthoyl)indole structure with substitution at the nitrogen atom of the OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.5 1099 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent.

26.293.19 5 1099 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent.

1-hexyl-3-(1-naphthoyl)indole(JWH-019);1-hexyl-3-(1-naphthoyl)indole (JWH-019);

(b) Naphthylmethylindoles.AnyNaphthylmethylindoles. compound containing a 1H-indol-2-yl-(1- naphthyl)methane or 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl2-(4-morpholinyl)ethylcyanoalky, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran- 4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent.

Any compound containing a 1H-indol-2-yl-(1- naphthyl)methane or 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran- 4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent.

Any compound containing a 2-phenylacetylindole or 3- phenylacetylindole structure with substitution at the nitrogen atom of the OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.6 1099 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent.

26.293.19 6 1099 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent.

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.7 1099 Some trade or other names:

26.293.19 7 1099 Some trade or other names:

Any compound containing a 2-acetyl indole or 3- acetyl indole structure substituted at the acetyl by replacement of the methyl group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde substituent whether or not further substituted on the tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.8 1099 substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted on the indole ring to any extent.

26.293.19 8 1099 substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted on the indole ring to any extent.

Any compound containing a 2-carboxamide indole or 3-carboxamide indole structure substituted at the nitrogen of the carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl, phenyl, or propionaldehyde substituent, whether or not further substituted on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,1-(N-methyl-2-cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran- 4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted on the indole ring to any extent.

1-(4- cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN- OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.9 1099 CUMYL-BUTINACA);

26.293.19 9 1099 CUMYL-BUTINACA);

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.10 1099 (51) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

26.293.19 10 1099 (51) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

(a) By substitutiononsubstitution on the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups;

25C- OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.11 1099 NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine);

26.293.19 11 1099 NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine);

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.12 1099 (72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB- PINACA);

26.293.19 12 1099 (72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB- PINACA);

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.13 1099 (15) Temazepam;

26.293.19 13 1099 (15) Temazepam;

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.14 1099 (48) Ezogabine,[-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester], including its salts, isomers, and salts of isomers;

26.293.19 14 1099 (48) Ezogabine,[-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester], including its salts, isomers, and salts of isomers;

(57) Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethylcarbamate;([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate;

OverstrikesHB1099 indicateENROLLED deleted26.293.20 language.15 1099 An Act to reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

Received at this Executive Office I certify that the attached Act originated in this _____ day of _____________, the:

at ____________M.

House as Bill No.